Abstract: Methods, apparatus, systems, and articles of manufacture to make and/or process a diagnostic test device are disclosed. An example apparatus includes a first portion including an opening; a second portion coupled to the first portion and house a lateral flow assay strip, the second portion including a first clip; and a push button located within the opening of the first portion, the push button moveable from a first position to a second position, the push button including a second clip to engage the first clip of the second portion to maintain the push button in the second position when moved into the second position.

Abstract: Methods, apparatus, systems, and articles of manufacture to make and/or process a diagnostic test device are disclosed. An example apparatus includes a sensor to measure a current between a first electrode and a second electrode of a bioelectrochemical cell coupled to a test zone corresponding to a target analyte on a porous media of a device; a processor to compare the current to a threshold; and when the current is more than the threshold, identify that the target analyte is present in a sample; and an antenna to wirelessly transmit results.

Abstract: Implementations include providing, by a deploy tool, clone data components in the first database system, each clone data component being a copy of a data component, defining, by the deploy tool, a source-side green access schema in the first database system, the green access schema providing views to the clone data components, providing, by a replication system and based on statements received from the deploy tool, consumer-side clone data components in the first database system, each consumer-side clone data component being a copy of a respective data component, defining, by a replication system and based on statements received from the deploy tool, a consumer-side green access schema in the first database system, the green access schema providing views to the source-side clone data components, and, during execution of the upgrade, replicating, by a handler of the replication system, data from at least one source-side data component to a consumer-side component.

Abstract: The present invention provides a compound of formula (I) in free form or in pharmaceutically acceptable salt form a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

Abstract: The invention relates to a compound of Formula I or a pharmaceutically acceptable salt thereof, a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

Abstract: The present invention provides a compound of formula (I) in free form or in pharmaceutically acceptable salt form a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

Abstract: The invention relates to devices and methods for the detection of specific interactions between probe and target molecules. In particular, the invention relates to methods for the qualitative and/or quantitative detection of targets, including: introducing a sample containing targets into a reaction chamber formed between a first surface of the device and a second surface of a device, which is preferably located opposite to the first surface, wherein the distance between the first and the second surface is variable; and detecting the targets.

Abstract: The invention relates to a compound of formula (1) in free form or in pharmaceutically acceptable salt form to pharmaceutical compositions comprising said compound and to the use of said compound in the treatment of heterotopic ossification and fibrodysplasia ossificans progressiva.

Abstract: The invention relates to a compound of formula (I) in free form or in pharmaceutically acceptable salt form to pharmaceutical compositions comprising said compound and to the use of said compound in the treatment of heterotopic ossification and fibrodysplasia ossificans progressiva.

Abstract: The invention relates to a compound of Formula I or a pharmaceutically acceptable salt thereof, a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

Abstract: The present invention relates to methods for determining the presence and/or amount of multiple nucleic acids in a sample.

Abstract: The invention relates to a compound of formula (I) in free form or in pharmaceutically acceptable salt form to pharmaceutical compositions comprising said compound and to the use of said compound in the treatment of heterotopic ossification and fibrodysplasia ossificans progressiva.

Abstract: The present invention provides a compound of formula (I) in free form or in pharmaceutically acceptable salt form, a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

Abstract: The invention relates to a compound of formula (I) in free form or in pharmaceutically acceptable salt form (I) to pharmaceutical compositions comprising said compound and to the use of said compound in the treatment of heterotopic ossification and fibrodysplasia ossificans progressiva.

Abstract: Implementations include providing, by a deploy tool, clone data components in the first database system, each clone data component being a copy of a data component, defining, by the deploy tool, a source-side green access schema in the first database system, the green access schema providing views to the clone data components, providing, by a replication system and based on statements received from the deploy tool, consumer-side clone data components in the first database system, each consumer-side clone data component being a copy of a respective data component, defining, by a replication system and based on statements received from the deploy tool, a consumer-side green access schema in the first database system, the green access schema providing views to the source-side clone data components, and, during execution of the upgrade, replicating, by a handler of the replication system, data from at least one source-side data component to a consumer-side component.

Abstract: In order to perform relatively frequent, zero-downtime software updates, a bridge schema corresponding to an original schema of a database system may be generated. Within the bridge schema, a plurality of views corresponding to a plurality of database tables of an application executing on an application server may be generated. A connection from the application to the original schema may be changed to the bridge schema, to thereby continue executing the application using the plurality of views. When a change file defining update changes to at least one original database table of the plurality of database tables is received, content of the at least one original database table may be synchronized with a target table reflecting the update changes. Then, the connection may be changed back to the original database schema to continue executing the software application, using the plurality of database tables and including the target table.

Abstract: The present invention relates to methods for determining the presence and/or amount of multiple nucleic acids in a sample.

Abstract: The present invention provides a compound of formula (I) in free form or in pharmaceutically acceptable salt form, a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

Abstract: Various techniques are described for precisely locking database objects within a database during a system upgrade with the use of database freeze triggers. Some database freeze triggers can be utilized to lock transport requests while other database freeze triggers can be utilized to lock database objects such as exchange tables. For transport requests, techniques describe the use of a whitelist identify transport objects or transport object types which shall remain unblocked. As a result, a database freeze trigger can be generated for transport objects or transport object types that are not included in the whitelist. For database objects, techniques describe the identification of a tool or service which has been allowed during the upgrade. Database objects which can be modified during execution of the tool or service can be identified. Database freeze triggers can be generated for the database objects besides those identified.